´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.

TransIT¢ç-293 Transfection Reagent

-

Á¦Á¶»ç Á¦Ç°ÄÚµå Á¦Ç°¸í ¿ë·® °¡°Ý
(ºÎ°¡¼¼º°µµ)
ºñ°í »ç¿ëÀڸŴº¾ó
Mirus
MIR 2704
TransIT-293 Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
0.4 ml
°¡°Ý¹®ÀÇ   °¡°ÝÇÒÀÎ
11.01 ~ 12.27
ml009_transit_293_transfection_reagent.pdf
Mirus
MIR 2700
TransIT-293 Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱ⠻ùÇýÅû 
1 ml
°¡°Ý¹®ÀÇ   °¡°ÝÇÒÀÎ
11.01 ~ 12.27
Mirus
MIR 2705
TransIT-293 Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
1 ml¡¿5
°¡°Ý¹®ÀÇ   °¡°ÝÇÒÀÎ
11.01 ~ 12.27
Mirus
MIR 2706
TransIT-293 Transfection Reagent
°ü·ÃÇмú ±¸¸ÅÇϱâ
1 ml¡¿10
°¡°Ý¹®ÀÇ   °¡°ÝÇÒÀÎ
11.01 ~ 12.27

  • Unique Formulation - Maximize transfection performance in HEK 293 cells.
  • Low Cellular Toxicity - Maintain cell density and reduce experimental biases.
  • High Efficiency Delivery - Achieve 75-85% transfection efficiency to ensure experimental success.
  • Deliver Single or Multiple Plasmids - Ideal for specialized applications, such as viral production.
Recent publications citing the use of TransIT-293 Transfection Reagent for lentiviral production

A lentiviral vector encoding two fluorescent proteins enables imaging of adenoviral infection via adenovirus-encoded miRNAs in single living cells
Yoshio Kato, Shinya Y. Sawata, and Atsushi Inoue
J. Biochem., Jan 2010; 147: 63 - 71. Pubmed

Analysis of the Role of Tripeptidyl Peptidase II in MHC Class I Antigen Presentation In Vivo
Masahiro Kawahara, Ian A. York, Arron Hearn, Diego Farfan, and Kenneth L. Rock
J. Immunol., Nov 2009; 183: 6069 - 6077. Pubmed

Down-Regulation of Class II Phosphoinositide 3-Kinase Expression below a Critical Threshold Induces Apoptotic Cell Death
Winfried Elis, Ellen Triantafellow, Natalie M. Wolters, Katie R. Sian, Giordano Caponigro, Jason Borawski, L. Alex Gaither, Leon O. Murphy, Peter M. Finan, and Jeffrey P. MacKeigan
Mol. Cancer Res., Apr 2008; 6: 614 - 623.

Recent publications citing the use of TransIT-293 Transfection Reagent for retroviral production

Assembly Properties of Human Immunodeficiency Virus Type 1 Gag-Leucine Zipper Chimeras: Implications for Retrovirus Assembly
Rachael M. Crist, Siddhartha A. K. Datta, Andrew G. Stephen, Ferri Soheilian, Jane Mirro, Robert J. Fisher, Kunio Nagashima, and Alan Rein
J. Virol., Mar 2009; 83: 2216 - 2225. Pubmed

Interactions of Murine APOBEC3 and Human APOBEC3G with Murine Leukemia Viruses
Samuel J. Rulli, Jr., Jane Mirro, Shawn A. Hill, Patricia Lloyd, Robert J. Gorelick, John M. Coffin, David Derse, and Alan Rein
J. Virol., Jul 2008; 82: 6566 - 6575. Pubmed

The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Sokol Haxhinasto, Diane Mathis, and Christophe Benoist
J. Exp. Med., Mar 2008; 205: 565 - 574. Pubmed




Figure 1. The TransIT-293 Reagent Achieves High Transfection Efficiency. HEK 293 cells transfected with pEGFP using TransIT-293 Reagent in complete media for 24 hours.

Keyword : V2700,MIR2700,V2704,MIR2704,V2705,MIR2705,V2706,MIR2706